0	9	C/EBPbeta	C/EBPbeta	NNP
10	13	and	and	CC
14	20	GATA-1	GATA-1	NNP
21	36	synergistically	synergistically	RB
37	45	regulate	regulate	VBP
46	54	activity	activity	NN
55	57	of	of	IN
58	61	the	the	DT
62	72	eosinophil	eosinophil	NN
73	80	granule	granule	NN
81	86	major	major	JJ
87	92	basic	basic	JJ
93	100	protein	protein	NN
101	109	promoter	promoter	NN
109	110	:	:	:
111	122	implication	implication	NN
123	126	for	for	IN
127	136	C/EBPbeta	C/EBPbeta	NNP
137	145	activity	activity	NN
146	148	in	in	IN
149	159	eosinophil	eosinophil	NN
160	164	gene	gene	NN
165	175	expression	expression	NN
175	176	.	.	.

178	188	Eosinophil	Eosinophil	NNP
189	196	granule	granule	NN
197	202	major	major	JJ
203	208	basic	basic	JJ
209	216	protein	protein	NN
217	218	(	(	(
218	221	MBP	MBP	NNP
221	222	)	)	)
223	225	is	be	VBZ
226	235	expressed	express	VBN
236	247	exclusively	exclusively	RB
248	250	in	in	IN
251	262	eosinophils	eosinophil	NNS
263	266	and	and	CC
267	276	basophils	basophil	NNS
277	279	in	in	IN
280	293	hematopoietic	hematopoietic	JJ
294	299	cells	cell	NNS
299	300	.	.	.

301	303	In	in	IN
304	307	our	our	PRP$
308	316	previous	previous	JJ
317	322	study	study	NN
322	323	,	,	,
324	326	we	we	PRP
327	339	demonstrated	demonstrate	VBD
340	341	a	a	DT
342	347	major	major	JJ
348	356	positive	positive	JJ
357	367	regulatory	regulatory	JJ
368	372	role	role	NN
373	376	for	for	IN
377	383	GATA-1	gata-1	NN
384	387	and	and	CC
388	389	a	a	DT
390	398	negative	negative	JJ
399	409	regulatory	regulatory	JJ
410	414	role	role	NN
415	418	for	for	IN
419	425	GATA-2	gata-2	NN
426	428	in	in	IN
429	432	MBP	MBP	NNP
433	437	gene	gene	NN
438	451	transcription	transcription	NN
451	452	.	.	.

453	460	Further	further	JJ
461	469	analysis	analysis	NN
470	472	of	of	IN
473	476	the	the	DT
477	480	MBP	MBP	NNP
481	489	promoter	promoter	NN
490	496	region	region	NN
497	507	identified	identify	VBD
508	509	a	a	DT
510	515	C/EBP	C/EBP	NNP
516	517	(	(	(
517	539	CCAAT/enhancer-binding	ccaat/enhancer-binding	JJ
540	547	protein	protein	NN
547	548	)	)	)
549	558	consensus	consensus	NN
559	566	binding	binding	NN
567	571	site	site	NN
572	573	6	6	CD
574	576	bp	bp	NN
577	585	upstream	upstream	RB
586	588	of	of	IN
589	592	the	the	DT
593	603	functional	functional	JJ
604	616	GATA-binding	gata-binding	JJ
617	621	site	site	NN
622	624	in	in	IN
625	628	the	the	DT
629	632	MBP	MBP	NNP
633	637	gene	gene	NN
637	638	.	.	.

639	641	In	in	IN
642	645	the	the	DT
646	650	cell	cell	NN
651	655	line	line	NN
656	661	HT93A	HT93A	NNP
661	662	,	,	,
663	668	which	which	WDT
669	671	is	be	VBZ
672	679	capable	capable	JJ
680	682	of	of	IN
683	698	differentiating	differentiate	VBG
699	706	towards	towards	IN
707	711	both	both	CC
712	715	the	the	DT
716	726	eosinophil	eosinophil	NN
727	730	and	and	CC
731	741	neutrophil	neutrophil	NN
742	750	lineages	lineage	NNS
751	753	in	in	IN
754	762	response	response	NN
763	765	to	to	TO
766	774	retinoic	retinoic	JJ
775	779	acid	acid	NN
780	781	(	(	(
781	783	RA	RA	NNP
783	784	)	)	)
784	785	,	,	,
786	796	C/EBPalpha	C/EBPalpha	NNP
797	801	mRNA	mRNA	NNP
802	812	expression	expression	NN
813	822	decreased	decrease	VBD
823	836	significantly	significantly	RB
837	848	concomitant	concomitant	JJ
849	853	with	with	IN
854	866	eosinophilic	eosinophilic	JJ
867	870	and	and	CC
871	883	neutrophilic	neutrophilic	JJ
884	899	differentiation	differentiation	NN
899	900	,	,	,
901	908	whereas	whereas	IN
909	918	C/EBPbeta	C/EBPbeta	NNP
919	929	expression	expression	NN
930	933	was	be	VBD
934	942	markedly	markedly	RB
943	952	increased	increase	VBN
952	953	.	.	.

954	969	Electrophoretic	electrophoretic	JJ
970	978	mobility	mobility	NN
979	984	shift	shift	NN
985	991	assays	assay	NNS
992	993	(	(	(
993	998	EMSAs	EMSA	NNP
998	999	)	)	)
1000	1006	showed	show	VBD
1007	1011	that	that	IN
1012	1023	recombinant	recombinant	JJ
1024	1033	C/EBPbeta	C/EBPbeta	NNP
1034	1041	protein	protein	NN
1042	1047	could	could	MD
1048	1052	bind	bind	VB
1053	1055	to	to	TO
1056	1059	the	the	DT
1060	1069	potential	potential	JJ
1070	1083	C/EBP-binding	c/ebp-binding	JJ
1084	1088	site	site	NN
1089	1090	(	(	(
1090	1092	bp	bp	NN
1093	1096	-90	-90	CD
1097	1099	to	to	TO
1100	1103	-82	-82	CD
1103	1104	)	)	)
1105	1107	in	in	IN
1108	1111	the	the	DT
1112	1115	MBP	MBP	NNP
1116	1124	promoter	promoter	NN
1124	1125	.	.	.

1126	1137	Furthermore	furthermore	RB
1137	1138	,	,	,
1139	1141	we	we	PRP
1142	1146	have	have	VBP
1147	1159	demonstrated	demonstrate	VBN
1160	1164	that	that	IN
1165	1169	both	both	CC
1170	1179	C/EBPbeta	C/EBPbeta	NNP
1180	1183	and	and	CC
1184	1190	GATA-1	GATA-1	NNP
1191	1194	can	can	MD
1195	1199	bind	bind	VB
1200	1214	simultaneously	simultaneously	RB
1215	1217	to	to	TO
1218	1221	the	the	DT
1222	1228	C/EBP-	c/ebp-	NN
1229	1232	and	and	CC
1233	1245	GATA-binding	gata-binding	JJ
1246	1251	sites	site	NNS
1252	1254	in	in	IN
1255	1258	the	the	DT
1259	1262	MBP	MBP	NNP
1263	1271	promoter	promoter	NN
1271	1272	.	.	.

1273	1275	To	to	TO
1276	1285	determine	determine	VB
1286	1289	the	the	DT
1290	1303	functionality	functionality	NN
1304	1306	of	of	IN
1307	1311	both	both	CC
1312	1315	the	the	DT
1316	1322	C/EBP-	c/ebp-	NN
1323	1326	and	and	CC
1327	1332	GATA-	gata-	NN
1333	1340	binding	binding	NN
1341	1346	sites	site	NNS
1346	1347	,	,	,
1348	1350	we	we	PRP
1351	1359	analyzed	analyze	VBD
1360	1367	whether	whether	IN
1368	1377	C/EBPbeta	C/EBPbeta	NNP
1378	1381	and	and	CC
1382	1388	GATA-1	GATA-1	NNP
1389	1392	can	can	MD
1393	1402	stimulate	stimulate	VB
1403	1406	the	the	DT
1407	1410	MBP	MBP	NNP
1411	1419	promoter	promoter	NN
1420	1422	in	in	IN
1423	1426	the	the	DT
1427	1436	C/EBPbeta	C/EBPbeta	NNP
1437	1440	and	and	CC
1441	1447	GATA-1	gata-1	NN
1448	1456	negative	negative	JJ
1457	1463	Jurkat	Jurkat	NNP
1464	1470	T-cell	T-cell	NNP
1471	1475	line	line	NN
1475	1476	.	.	.

1477	1491	Cotransfection	Cotransfection	NNP
1492	1496	with	with	IN
1497	1506	C/EBPbeta	C/EBPbeta	NNP
1507	1510	and	and	CC
1511	1517	GATA-1	gata-1	NN
1518	1528	expression	expression	NN
1529	1536	vectors	vector	NNS
1537	1545	produced	produce	VBD
1546	1547	a	a	DT
1548	1554	5-fold	5-fold	JJ
1555	1563	increase	increase	NN
1564	1572	compared	compare	VBN
1573	1577	with	with	IN
1578	1592	cotransfection	cotransfection	NN
1593	1597	with	with	IN
1598	1601	the	the	DT
1602	1611	C/EBPbeta	C/EBPbeta	NNP
1612	1614	or	or	CC
1615	1621	GATA-1	gata-1	NN
1622	1632	expression	expression	NN
1633	1640	vectors	vector	NNS
1641	1653	individually	individually	RB
1653	1654	.	.	.

1655	1657	In	in	IN
1658	1666	addition	addition	NN
1666	1667	,	,	,
1668	1671	GST	GST	NNP
1672	1681	pull-down	pull-down	JJ
1682	1693	experiments	experiment	NNS
1694	1706	demonstrated	demonstrate	VBD
1707	1708	a	a	DT
1709	1717	physical	physical	JJ
1718	1729	interaction	interaction	NN
1730	1737	between	between	IN
1738	1743	human	human	JJ
1744	1750	GATA-1	gata-1	NN
1751	1754	and	and	CC
1755	1764	C/EBPbeta	C/EBPbeta	NNP
1764	1765	.	.	.

1766	1776	Expression	expression	NN
1777	1779	of	of	IN
1780	1783	FOG	FOG	NNP
1784	1785	(	(	(
1785	1790	riend	riend	NN
1791	1794	ATA	ATA	NNP
1794	1795	)	)	)
1795	1796	,	,	,
1797	1802	which	which	WDT
1803	1808	binds	bind	VBZ
1809	1811	to	to	TO
1812	1818	GATA-1	gata-1	NN
1819	1822	and	and	CC
1823	1827	acts	act	VBZ
1828	1830	as	as	IN
1831	1832	a	a	DT
1833	1841	cofactor	cofactor	NN
1842	1845	for	for	IN
1846	1858	GATA-binding	gata-binding	JJ
1859	1867	proteins	protein	NNS
1867	1868	,	,	,
1869	1878	decreased	decrease	VBD
1879	1894	transactivation	transactivation	NN
1895	1903	activity	activity	NN
1904	1906	of	of	IN
1907	1913	GATA-1	gata-1	NN
1914	1917	for	for	IN
1918	1921	the	the	DT
1922	1925	MBP	MBP	NNP
1926	1934	promoter	promoter	NN
1935	1937	in	in	IN
1938	1939	a	a	DT
1940	1954	dose-dependent	dose-dependent	JJ
1955	1961	manner	manner	NN
1961	1962	.	.	.

1963	1966	Our	our	PRP$
1967	1974	results	result	NNS
1975	1982	provide	provide	VBP
1983	1986	the	the	DT
1987	1992	first	first	JJ
1993	2001	evidence	evidence	NN
2002	2006	that	that	IN
2007	2011	both	both	CC
2012	2018	GATA-1	gata-1	NN
2019	2022	and	and	CC
2023	2032	C/EBPbeta	C/EBPbeta	NNP
2033	2048	synergistically	synergistically	RB
2049	2062	transactivate	transactivate	VBP
2063	2066	the	the	DT
2067	2075	promoter	promoter	NN
2076	2078	of	of	IN
2079	2081	an	an	DT
2082	2101	eosinophil-specific	eosinophil-specific	JJ
2102	2109	granule	granule	NN
2110	2117	protein	protein	NN
2118	2122	gene	gene	NN
2123	2126	and	and	CC
2127	2131	that	that	IN
2132	2135	FOG	FOG	NNP
2136	2139	may	may	MD
2140	2143	act	act	VB
2144	2146	as	as	IN
2147	2148	a	a	DT
2149	2157	negative	negative	JJ
2158	2166	cofactor	cofactor	NN
2167	2170	for	for	IN
2171	2174	the	the	DT
2175	2185	eosinophil	eosinophil	NN
2186	2193	lineage	lineage	NN
2193	2194	,	,	,
2195	2201	unlike	unlike	IN
2202	2205	its	its	PRP$
2206	2216	positively	positively	RB
2217	2227	regulatory	regulatory	JJ
2228	2236	function	function	NN
2237	2240	for	for	IN
2241	2244	the	the	DT
2245	2254	erythroid	erythroid	JJ
2255	2258	and	and	CC
2259	2272	megakaryocyte	megakaryocyte	NN
2273	2281	lineages	lineage	NNS
2281	2282	.	.	.